Literature DB >> 12763212

Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.

F Grossi1, M Loprevite, M Chiaramondia, P Ceppa, C Pera, G B Ratto, J Serrano, G B Ferrara, R Costa, L Boni, A Ardizzoni.   

Abstract

The aim of this study was to investigate the prognostic significance of a panel of biological parameters in patients with radically resected non-small cell lung cancers (NSCLC). 269 cases with pathological stage I-IIIA NSCLC were retrospectively analysed. Immunohistochemistry was performed to detect protein expression of p53, bcl-2, proliferating cell nuclear antigen (PCNA) and CD34. Polymerase chain reaction (PCR)/direct nucleotide sequencing method was used to detect mutations in K-ras (codons 12, 13, 61, exons 1-2). The Kaplan-Meier estimates of survival were calculated for clinical and biological variables using the Cox model for multivariate analysis. Histological subtype and the pathologic tumour extension (pT) were the most powerful clinical-pathological prognostic factors for survival (P=0.030 and P=0.031, respectively), whereas among the biological parameters, p53 overexpression (P=0.032) and K-ras mutation (P=0.078) had a negative prognostic role, as demonstrated by multivariate analysis. Conversely, bcl-2, PCNA and CD34 expression were not correlated with survival. Statistically significant associations between p53 expression and the squamous cell carcinoma (SCC) subtype, bcl-2 expression and SCC subtype, K-ras mutation and p53 negative expression, p53 and bcl-2, bcl-2 and PCNA overexpression were observed. In conclusion, some biological characteristics such as the K-ras and p53 status may provide useful prognostic information in resected NSCLC patients, in addition to the classical clinico-pathological parameters. However, further studies are needed to clarify the value of adopting biological prognostic factor into clinical practice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763212     DOI: 10.1016/s0959-8049(03)00232-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  17 in total

1.  The value of serum Bcl-2 levels in advanced lung cancer patients.

Authors:  Faruk Tas; Derya Duranyildiz; Hilal Oguz; Hakan Camlica; Ethem Nezih Oral; Vildan Yasasever; Erkan Topuz
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 2.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  Targeting tyrosine phosphorylation of PCNA inhibits prostate cancer growth.

Authors:  Huajun Zhao; Yuan-Hung Lo; Li Ma; Susan E Waltz; Jerilyn K Gray; Mien-Chie Hung; Shao-Chun Wang
Journal:  Mol Cancer Ther       Date:  2011-01       Impact factor: 6.261

4.  Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer.

Authors:  Ning Li; Wenying Deng; Jie Ma; Bing Wei; Kang Guo; Wei Shen; Yanping Zhang; Suxia Luo
Journal:  Med Oncol       Date:  2014-12-10       Impact factor: 3.064

5.  KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.

Authors:  Kyuichi Kadota; Camelia S Sima; Maria E Arcila; Cyrus Hedvat; Mark G Kris; David R Jones; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

6.  How close are we to customizing chemotherapy in early non-small cell lung cancer?

Authors:  Georgios Ioannidis; Vassilis Georgoulias; John Souglakos
Journal:  Ther Adv Med Oncol       Date:  2011-07       Impact factor: 8.168

Review 7.  Are we ready to use biomarkers for staging, prognosis and treatment selection in early-stage non-small-cell lung cancer?

Authors:  Bartomeu Massuti; Jose Miguel Sanchez; Florentino Hernando-Trancho; Niki Karachaliou; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2013-06

Review 8.  A translational approach to lung cancer research: From EGFRs to Wnt and cancer stem cells.

Authors:  Adam Yagui-Beltrán; David M Jablons
Journal:  Ann Thorac Cardiovasc Surg       Date:  2009-08       Impact factor: 1.520

9.  Overexpression of PELP1 in Lung Adenocarcinoma Promoted E2 Induced Proliferation, Migration and Invasion of the Tumor Cells and Predicted a Worse Outcome of the Patients.

Authors:  Dongmei Zhang; Jiali Dai; Yu Pan; Xiuli Wang; Juanjuan Qiao; Hironobu Sasano; Baoshan Zhao; Keely M McNamara; Xue Guan; Lili Liu; Yanzhi Zhang; Monica S M Chan; Shuwen Cao; Ming Liu; Sihang Song; Lin Wang
Journal:  Pathol Oncol Res       Date:  2021-04-02       Impact factor: 3.201

10.  Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides.

Authors:  Yung-Luen Yu; Ruey-Hwang Chou; Jia-Hong Liang; Wei-Jung Chang; Kuo-Jung Su; Yen-Ju Tseng; Wei-Chien Huang; Shao-Chun Wang; Mien-Chie Hung
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.